Clinical Integration

Changing Lives Through Research

‘Dragon Heart’ Holds
Promise as Flexible,
Cost-Effective Treatment
for Heart Failure

General Surgery Continues Journey
as Enterprise Service Line

Drs. Amy Throckmorton (on sabbatical from Drexel University) and Vakhtang Tchantchaleisvilli are collaborating
locally on a new cardiac assist and replacement device as part of a national team funded by NIH. The laboratory is
located in the College Building on Walnut Street.

Could congestive heart failure (CHF)
be treated with a total artificial heart
that contains just two moving parts?
That’s one of the questions that
cardiac surgeon, Vakhtang
Tchantchaleishvili, MD, and biomedical
engineer Amy L. Throckmorton, PhD,
an associate professor at the Drexel
University School of Biomedical
Engineering, Science and Health
Systems, are collaborating to answer.
Known as “Dragon Heart,” the device
they are testing is an advanced cardiac
assist and replacement technology
designed and developed by Dr.
Throckmorton, who is currently on
sabbatical at Jefferson. She and Dr.
Tchantchaleishvili are part of a national
team that in July 2020 secured a fouryear, $1.5 million research grant from
the National Heart, Lung, and Blood
Institute within the National Institutes
of Health to support this pre-clinical
development phase.
If proven effective, the Dragon Heart
would offer a compact, multifunctional total artificial heart that
could help both adult and pediatric
patients with CHF. To do so, it relies
on two moving parts: an axial impeller
for pulmonary circulation and a
centrifugal impeller for systemic
circulation.
CHF is a costly disease in terms of
human and financial impact. This
progressive and debilitating disease
affects about 5.1 million people in the
United States alone, with about
670,000 new cases diagnosed every
year. Treating patients with CHF costs
the healthcare industry more than
$35 billion annually, and existing
treatments, including transplantation,

are not always available or effective
for all patients.
“My vision of the Dragon Heart has
been to provide as much versatility as
possible in giving clinical management
teams the ability to offer the right
treatment for the right patient at the
right time,” says Dr. Throckmorton,
who used pump design equations,
computational modeling, and
benchtop prototype testing to inform
device design and performance.
The Dragon Heart has been designed
to support the left or right side of the
heart, to partially support both
ventricles, or to fully support both
ventricles as a total artificial heart,
providing a viable alternative to heart
transplantation. Dr. Tchantchaleishvili
puts it even more succinctly –
referring to the Dragon Heart as
“the Batmobile of cardiac assist and
replacement technologies.”
Dr. Tchantchaleishvili says the device is
also noteworthy because of its use of
full magnetic levitation technology,
one of most recent innovations in
cardiac replacement technology.
“The Dragon Heart is one of only
three total artificial hearts that are
continuous-flow devices,” he says.
“This device also supports pulsatile
flow, adding to its clinical versatility.”
While at Jefferson, Dr. Throckmorton
is continuing to build prototypes of
the Dragon Heart and is working
with Dr. Tchantchaleishvili, H. Todd
Massey, MD, Surgical Director, Cardiac
Transplantation and Mechanical
Circulatory Support, and others to
prepare for additional studies of the
device’s efficacy.

As Jefferson Health has grown to
include 14 acute-care hospitals, the
system continues to make the strategic
shift from “holding company” to
“operating company.” The General
Surgery service line – which includes
all services within the Department of
Surgery except for Cardiac, Thoracic,
Transplant and Vascular – has made
significant progress in the journey to a
truly enterprise approach.

“For example, a surgeon from one of our
hospitals may have a recommendation
for a new surgical service, device or
technique,” says Messer, who assumed
administrative responsibility for the
General Surgery service line last
December. “We’re now evaluating such
proposals at the enterprise level. Based
on the idea’s merits, we may decide to
put it on pause, or we may opt to deploy
it across the service line.”

With the General Surgery service line
formally established in October 2019,
surgical leaders from across Jefferson
Health have converged around shared
strategic planning and clinical and
operational support.

In addition to the ISFP, the General
Surgery service line is working to create
a series of Clinical Pathways (CPs)
to establish consistency in surgical
patient diagnosis, treatment and
follow-up. Each CP will outline the most
appropriate, evidence-based standard of
care that every Jefferson Health surgeon
should follow when delivering a specific
procedure.

“Greater communication and
transparency are critical when making
a shift to an enterprise model. There is
always more work to do, but we have
made great progress,” says Charles J.
Yeo, MD, who leads the service line in
his capacity as Senior Vice President
and Chair, Enterprise Surgery, Jefferson
Health. Other General Surgery leaders
include Mohammad I. Khan, MD, Vice
Chair at Jefferson Health – Northeast,
Orlando Kirton, MD, Vice Chair at
Jefferson Health – Abington, Roy L.
Sandau, DO, Vice Chair at Jefferson
Health – New Jersey, and Francesco
Palazzo, MD, Vice Chair at Jefferson
Methodist Hospital.
As Vice President and Service Line
Administrator Adam Messer explains,
the Integrated Strategic Financial
Planning (ISFP) process is serving as
the formal process and mechanism
to ensure that general surgeons are
operating not as individual physicians
or hospitals, but as an enterprise.

“I’m thankful to be collaborating with
Dr. Tchantchaleishvili and his team to
complete the critical acute testing
studies in animals,” Dr. Throckmorton
says. “These are a necessary step
toward achieving successful
translation of the Dragon Heart
blood pump technology. His

“Think of Clinical Pathways as a guardrail
around a particular clinical episode
that ensure we have consistently good
outcomes,” Messer says. “We want to use
evidence and consensus to ensure that
no matter who your surgeon is or where
your surgery is performed, you’ll have
the same type of care.”
Messer notes that the upcoming
enterprise launch of the Epic electronic
medical record (EMR) system to include
all Jefferson Health hospitals will be
critical enabler for CPs.
“The 2021 launch of Epic will put
everyone on the same integrated EMR
from inpatient to outpatient and will
be a foundational tool for developing
CPs and establishing enterprise-wide
standards of care,” Messer concludes.

research team at Jefferson is ideally
suited to lead and conduct these
animal studies.”
For more information, please visit:
Research.Jefferson.edu/labs/
researcher/tchantchaleishvililaboratory.html
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